Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
China’s Zero-COVID Restrictions Can’t Stop JD.com
This Govt. Act Can Help Investors (Ad)
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
China’s Zero-COVID Restrictions Can’t Stop JD.com
This Govt. Act Can Help Investors (Ad)
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
China’s Zero-COVID Restrictions Can’t Stop JD.com
This Govt. Act Can Help Investors (Ad)
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
China’s Zero-COVID Restrictions Can’t Stop JD.com
This Govt. Act Can Help Investors (Ad)
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
NASDAQ:SMMT

Summit Therapeutics - SMMT Stock Forecast, Price & News

$0.94
+0.02 (+2.17%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.90
$0.96
50-Day Range
$0.89
$1.35
52-Week Range
$0.86
$5.30
Volume
112,951 shs
Average Volume
140,299 shs
Market Capitalization
$189.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SMMT stock logo

About Summit Therapeutics (NASDAQ:SMMT) Stock

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMMT Stock News Headlines

Summit Therapeutics Inc. (SMMT)
Why Summit Therapeutics Stock Popped Today
Why Summit Therapeutics Stock Is Soaring Today
SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc. Common Stock (SMMT)
See More Headlines
Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMMT Company Calendar

Last Earnings
11/15/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMMT
Employees
105
Year Founded
N/A

Profitability

Net Income
$-88,600,000.00
Net Margins
-1,012.41%
Pretax Margin
-1,012.41%

Debt

Sales & Book Value

Annual Sales
$22.78 million
Book Value
$0.85 per share

Miscellaneous

Free Float
40,244,000
Market Cap
$189.24 million
Optionable
Optionable
Beta
0.86

Key Executives

  • Mr. Robert W. DugganMr. Robert W. Duggan (Age 78)
    CEO & Exec. Chairman
  • Dr. Mahkam Zanganeh D.D.S. (Age 52)
    M.B.A., MBA, Co-CEO, Pres & Director
    Comp: $651.45k
  • Dr. Urte Gayko Ph.D. (Age 51)
    Head of Regulatory Affairs, Quality Assurance & Safety and Director
    Comp: $7.76k
  • Prof. Dame Kay Davies DBE (Age 71)
    FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Mr. Ankur Dhingra (Age 46)
    Chief Financial Officer
  • Ms. Michelle Avery
    Director of Investor Relations
  • Dr. Elaine Carla Stracker J.D. (Age 61)
    Ph.D., Head of Compliance? & Gen. Counsel
  • Mr. Campbell Hair
    Head of HR?
  • Dr. Anne Heatherington
    Head of Clinical Devel. and Quantitative Sciences
  • Ms. Divya Chari (Age 54)
    Head of Global Clinical Operations













SMMT Stock - Frequently Asked Questions

Should I buy or sell Summit Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SMMT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View SMMT analyst ratings
or view top-rated stocks.

How have SMMT shares performed in 2022?

Summit Therapeutics' stock was trading at $2.69 at the beginning of the year. Since then, SMMT stock has decreased by 65.1% and is now trading at $0.94.
View the best growth stocks for 2022 here
.

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our SMMT earnings forecast
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.09. The company had revenue of $6.12 million for the quarter. Summit Therapeutics had a negative trailing twelve-month return on equity of 104.32% and a negative net margin of 1,012.41%.

What other stocks do shareholders of Summit Therapeutics own?
When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.43%), Marshall Wace LLP (0.14%) and UBS Group AG (0.05%). Insiders that own company stock include Ankur Dhingra, David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends
.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $0.94.

How much money does Summit Therapeutics make?

Summit Therapeutics (NASDAQ:SMMT) has a market capitalization of $189.24 million and generates $22.78 million in revenue each year. The company earns $-88,600,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Summit Therapeutics have?

The company employs 105 workers across the globe.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The official website for the company is www.summitplc.com. The company can be reached via phone at 617-514-7149, via email at investors@summitplc.com, or via fax at 44-12-3544-3999.

This page (NASDAQ:SMMT) was last updated on 11/29/2022 by MarketBeat.com Staff